About this Research Topic
Glycosylation is a complex non-template driven process whereby proteins and lipids are decorated with carbohydrates. These conjugated carbohydrates are among others involved in cell-cell interactions as well as protein-protein interactions and can have signaling capacity, and are therefore important regulators in both normal hematology and hematological cancers. However, to date the area of glycobiology in hematology is still an underexplored field.
Because of the incomplete knowledge, the overall goal of this research topic on ‘Glycobiology in Hematology’ is to obtain more information about the impact of glycosylation on normal hematological processes (e.g. hematopoiesis, immune cell development and functioning) as well as hematological cancers (e.g. leukemia and lymphoma) and to investigate their use for diagnostics and cancer therapy. To this end, the glycome of hematological (cancer) cells should be identified and research has to be performed to delineate how glycosylation steers anti-cancer (immune) therapy. Furthermore, glycosylation can be used as therapeutic target. In this respect it has become apparent in recent years that cancers commonly differ in their glycosylation pattern compared to healthy cells, and also within a certain cancer type heterogeneity exists. Furthermore, glycosylation has been associated with sensitivity for chemotherapy and can impact on the efficacy of anti-cancer immune responses.
We invite you to submit original research articles as well as review articles involving glycobiology in hematology which is including but not limited to:
- Glycomics: Analysis of glycomics of hematological (cancer) cells including method development.
- Pre-clinical Research: The impact of glycosylation on cancer cell behavior and response to therapy including chemotherapy and immunotherapy. Furthermore, the targeting of glycosylation as therapeutic strategy (e.g. cytotoxic lectins, glycosylation inhibitors etc.) is of interest.
- Clinical data: Studies that describe investigations or observations in relation to glycobiology in a clinical setting including case reports.
Because of the incomplete knowledge, the overall goal of this research topic on ‘Glycobiology in Hematology’ is to obtain more information about the impact of glycosylation on normal hematological processes (e.g. hematopoiesis, immune cell development and functioning) as well as hematological cancers (e.g. leukemia and lymphoma) and to investigate their use for diagnostics and cancer therapy. To this end, the glycome of hematological (cancer) cells should be identified and research has to be performed to delineate how glycosylation steers anti-cancer (immune) therapy. Furthermore, glycosylation can be used as therapeutic target. In this respect it has become apparent in recent years that cancers commonly differ in their glycosylation pattern compared to healthy cells, and also within a certain cancer type heterogeneity exists. Furthermore, glycosylation has been associated with sensitivity for chemotherapy and can impact on the efficacy of anti-cancer immune responses.
We invite you to submit original research articles as well as review articles involving glycobiology in hematology which is including but not limited to:
- Glycomics: Analysis of glycomics of hematological (cancer) cells including method development.
- Pre-clinical Research: The impact of glycosylation on cancer cell behavior and response to therapy including chemotherapy and immunotherapy. Furthermore, the targeting of glycosylation as therapeutic strategy (e.g. cytotoxic lectins, glycosylation inhibitors etc.) is of interest.
- Clinical data: Studies that describe investigations or observations in relation to glycobiology in a clinical setting including case reports.
Keywords: Glycans, Carbohydrates, Glycoproteins, Glycolipids, Biomarker, Therapeutic Target, AML, DLBCL, Heterogeneity, Glycomics, Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
